Literature DB >> 17244226

Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure.

Marcus Kernt, Aljoscha S Neubauer, Anselm Kampik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17244226     DOI： 10.1111/j.1600-0420.2006.00819.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN： 1395-3907


× No keyword cloud information.
  11 in total

1.  Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).

Authors:  Lihteh Wu; María A Martínez-Castellanos; Hugo Quiroz-Mercado; J Fernando Arevalo; María H Berrocal; Michel E Farah; Mauricio Maia; José A Roca; Francisco J Rodriguez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

Review 2.  [Intravitreal injection. Monitoring to avoid postoperative complications].

Authors:  C H Meyer; F Ziemssen; H Heimann
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

3.  Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study.

Authors:  Focke Ziemssen; Qi Zhu; Swaantje Peters; Salvatore Grisanti; Mohammed El Wardani; Peter Szurman; Karl U Bartz-Schmidt; Tjalf Ziemssen
Journal:  Int Ophthalmol       Date:  2008-04-17       Impact factor: 2.031

4.  Short-term effects of intravitreal ranibizumab and bevacizumab administration on 24-h ambulatory blood pressure monitoring recordings in normotensive patients with age-related macular degeneration.

Authors:  A Sengul; R Rasier; C Ciftci; O Artunay; A Kockar; H Bahcecioglu; E Yuzbasioglu
Journal:  Eye (Lond)       Date:  2017-01-06       Impact factor: 3.775

5.  [Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells].

Authors:  M Kernt; U Welge-Lüssen; A Yu; A S Neubauer; A Kampik
Journal:  Ophthalmologe       Date:  2007-11       Impact factor: 1.059

Review 6.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

7.  [Analysis of cardiovascular diseases after the upload phase with intravitreal ranibizumab and bevacizumab in patients with exudative age-related macular degeneration].

Authors:  C Fischer; K Schäfer; T Dschietzig; H Hoerauf
Journal:  Ophthalmologe       Date:  2016-07       Impact factor: 1.059

8.  Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration.

Authors:  Fengfu Li; Bernard Hurley; Yun Liu; Brian Leonard; May Griffith
Journal:  Open Ophthalmol J       Date:  2012-06-25

9.  Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: A prospective, randomized study.

Authors:  Rajvardhan Azad; Siddarth Sain; Yog Raj Sharma; Deepankur Mahajan
Journal:  Oman J Ophthalmol       Date:  2012-09

Review 10.  Bevacizumab: off-label use in ophthalmology.

Authors:  Salvatore Grisanti; Focke Ziemssen
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.